Product Details for NDA 214860
OLPRUVA (SODIUM PHENYLBUTYRATE)
2GM/PACKET
Marketing Status: Prescription
3GM/PACKET
Marketing Status: Prescription
4GM/PACKET
Marketing Status: Prescription
5GM/PACKET
Marketing Status: Prescription
6GM/PACKET
Marketing Status: Prescription
6.67GM/PACKET
Marketing Status: Prescription
2GM/PACKET
Marketing Status: Prescription
Active Ingredient: SODIUM PHENYLBUTYRATE
Proprietary Name: OLPRUVA
Dosage Form; Route of Administration: FOR SUSPENSION; ORAL
Strength: 2GM/PACKET
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N214860
Product Number: 001
Approval Date: Dec 22, 2022
Applicant Holder Full Name: ACER THERAPEUTICS INC
Marketing Status: Prescription
Patent and Exclusivity Information
OLPRUVA (SODIUM PHENYLBUTYRATE)
Proprietary Name: OLPRUVA
Dosage Form; Route of Administration: FOR SUSPENSION; ORAL
Strength: 2GM/PACKET
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N214860
Product Number: 001
Approval Date: Dec 22, 2022
Applicant Holder Full Name: ACER THERAPEUTICS INC
Marketing Status: Prescription
Patent and Exclusivity Information
3GM/PACKET
Marketing Status: Prescription
Active Ingredient: SODIUM PHENYLBUTYRATE
Proprietary Name: OLPRUVA
Dosage Form; Route of Administration: FOR SUSPENSION; ORAL
Strength: 3GM/PACKET
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N214860
Product Number: 002
Approval Date: Dec 22, 2022
Applicant Holder Full Name: ACER THERAPEUTICS INC
Marketing Status: Prescription
Patent and Exclusivity Information
OLPRUVA (SODIUM PHENYLBUTYRATE)
Proprietary Name: OLPRUVA
Dosage Form; Route of Administration: FOR SUSPENSION; ORAL
Strength: 3GM/PACKET
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N214860
Product Number: 002
Approval Date: Dec 22, 2022
Applicant Holder Full Name: ACER THERAPEUTICS INC
Marketing Status: Prescription
Patent and Exclusivity Information
4GM/PACKET
Marketing Status: Prescription
Active Ingredient: SODIUM PHENYLBUTYRATE
Proprietary Name: OLPRUVA
Dosage Form; Route of Administration: FOR SUSPENSION; ORAL
Strength: 4GM/PACKET
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N214860
Product Number: 003
Approval Date: Dec 22, 2022
Applicant Holder Full Name: ACER THERAPEUTICS INC
Marketing Status: Prescription
Patent and Exclusivity Information
OLPRUVA (SODIUM PHENYLBUTYRATE)
Proprietary Name: OLPRUVA
Dosage Form; Route of Administration: FOR SUSPENSION; ORAL
Strength: 4GM/PACKET
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N214860
Product Number: 003
Approval Date: Dec 22, 2022
Applicant Holder Full Name: ACER THERAPEUTICS INC
Marketing Status: Prescription
Patent and Exclusivity Information
5GM/PACKET
Marketing Status: Prescription
Active Ingredient: SODIUM PHENYLBUTYRATE
Proprietary Name: OLPRUVA
Dosage Form; Route of Administration: FOR SUSPENSION; ORAL
Strength: 5GM/PACKET
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N214860
Product Number: 004
Approval Date: Dec 22, 2022
Applicant Holder Full Name: ACER THERAPEUTICS INC
Marketing Status: Prescription
Patent and Exclusivity Information
OLPRUVA (SODIUM PHENYLBUTYRATE)
Proprietary Name: OLPRUVA
Dosage Form; Route of Administration: FOR SUSPENSION; ORAL
Strength: 5GM/PACKET
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N214860
Product Number: 004
Approval Date: Dec 22, 2022
Applicant Holder Full Name: ACER THERAPEUTICS INC
Marketing Status: Prescription
Patent and Exclusivity Information
6GM/PACKET
Marketing Status: Prescription
Active Ingredient: SODIUM PHENYLBUTYRATE
Proprietary Name: OLPRUVA
Dosage Form; Route of Administration: FOR SUSPENSION; ORAL
Strength: 6GM/PACKET
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N214860
Product Number: 005
Approval Date: Dec 22, 2022
Applicant Holder Full Name: ACER THERAPEUTICS INC
Marketing Status: Prescription
Patent and Exclusivity Information
OLPRUVA (SODIUM PHENYLBUTYRATE)
Proprietary Name: OLPRUVA
Dosage Form; Route of Administration: FOR SUSPENSION; ORAL
Strength: 6GM/PACKET
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N214860
Product Number: 005
Approval Date: Dec 22, 2022
Applicant Holder Full Name: ACER THERAPEUTICS INC
Marketing Status: Prescription
Patent and Exclusivity Information
6.67GM/PACKET
Marketing Status: Prescription
Active Ingredient: SODIUM PHENYLBUTYRATE
Proprietary Name: OLPRUVA
Dosage Form; Route of Administration: FOR SUSPENSION; ORAL
Strength: 6.67GM/PACKET
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N214860
Product Number: 006
Approval Date: Dec 22, 2022
Applicant Holder Full Name: ACER THERAPEUTICS INC
Marketing Status: Prescription
Patent and Exclusivity Information
Proprietary Name: OLPRUVA
Dosage Form; Route of Administration: FOR SUSPENSION; ORAL
Strength: 6.67GM/PACKET
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N214860
Product Number: 006
Approval Date: Dec 22, 2022
Applicant Holder Full Name: ACER THERAPEUTICS INC
Marketing Status: Prescription
Patent and Exclusivity Information